Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

FORE Biotherapeutics has announced that its plixorafenib abstract has been selected for poster presentation at the highly ...

NEW ORLEANS, La., May 7, 2025 /PRNewswire/ -- Mana.bio, a biotechnology company leveraging artificial intelligence (AI) and nanotechnology for targeted RNA delivery, today announced three poster ...

Codexis to showcase data that demonstrate the scalability and reproducibility of its enzymatic siRNA manufacturing processes Three CDMO presentations to feature data on performance of Codexis ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced the publication of 3 abstracts for poster presentations at the ...

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of ...

Discover groundbreaking research and presentations from leading companies at the ARVO 2025 Annual Meeting, advancing ...

A poster presentation will highlight new translational data monitoring ... In addition, two trials-in-progress presentations will showcase the design and scientific rationale of ongoing clinical ...

today announced the publication of 3 abstracts for poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025. In addition to a trial-in-progress study design ...

Adagene Inc. announced a poster presentation for the ASCO 2025 conference ... computational biology and artificial intelligence to design novel antibodies that address globally unmet patient ...